跳至主要内容
临床试验/DRKS00013497
DRKS00013497已完成不适用

Study on the incidence of genetic polymorphism in patients with major depression who are treated unsatisfactory with antidepressants - GENADET

STADAPHARM GmbH0 个研究点目标入组 252 人开始时间: 2017年12月8日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
252

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Outpatients with a diagnosis of major depression
  • First drug treatment with one of the following active substances since max. two weeks:
  • -Citalopram
  • -Escitalopram
  • -Amitriptyline
  • -Venlafaxine
  • Age =18 years
  • Capacity to consent

排除标准

  • Comedication with influence on the activity of the enzymes CYP2C19 and CYP2D6
  • Intake of St. John's wort preparations
  • Consumption of grapefruit and / or products
  • Consumption of tryptophan-containing dietary supplements
  • Change of medication within the last 3 months
  • Hepatic insufficiency (from Child-Pugh-stage A)
  • Renal insufficiency stage 3 (glomerular filtration rate <60 ml / min / 1.73 m²)
  • Addiction
  • Schizophrenia
  • Bipolar affective disorder
  • Pregnancy or breastfeeding
  • Participation in an interventional study

研究者

相似试验